Printer Friendly

FDA APPROVES CYTOGEN PRODUCT AS FIRST MAB-BASED CANCER IMAGING AGENT IN THE UNITED STATES

 PRINCETON, N.J., Dec. 30 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today that the Food and Drug Administration has granted marketing approval for OncoScint(R) CR/OV, the company's diagnostic agent for colorectal and ovarian adenocarcinoma.
 OncoScint CR/OV is the first monoclonal antibody-based cancer imaging agent approved in the United States. The product will be co-promoted by Cytogen and Knoll Pharmaceutical Company, the U.S.-based pharmaceutical operation owned by B.A.S.F. A.G. and its subsidiary, Knoll A.G., a major worldwide pharmaceutical company.
 OncoScint CR/OV is a diagnostic imaging agent that is indicated for determining the extent and location of extrahepatic malignant disease in patients with known colorectal or ovarian cancer. The diagnostic images acquired with OncoScint CR/OV should be interpreted in conjunction with a review of information obtained from other appropriate tests.
 Colorectal cancer is the second most common malignancy in the world, striking an estimated 150,000 individuals in the United States annually. Ovarian cancer accounts for 4 percent of all cancers among women, with an estimated 21,000 new cases in the United States annually.
 Cytogen is a biopharmaceutical company engaged in the development of products utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. Cytogen uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 12/30/92
 /CONTACT: Martin D. Cleary, group vp of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation; Food and Drug Administration; Knoll
 Pharmaceutical Company ST: New Jersey IN: MTC SU:


LJ -- PH002 -- 0525 12/30/92 09:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 30, 1992
Words:273
Previous Article:MOBIL STARTS CONSTRUCTION ON $90 MILLION DIESEL-PRODUCTION UNIT AT SINGAPORE REFINERY
Next Article:BURNHAM WINS TRADEMARK INFRINGEMENT SUIT
Topics:


Related Articles
CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH
CYTOGEN SCIENTISTS HONORED BY R&D COUNCIL OF NEW JERSEY
CYTOGEN REPORTS FAVORABLE REPEAT ADMINISTRATION RESULTS IN COLORECTAL CANCER IMAGING
ONCOSCINT(R) CR103 REPEAT ADMINISTRATION AMENDMENT RECOMMENDED FOR APPROVAL IN EUROPE
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN SUBMITS PROSTASCINT(TM) PRODUCT LICENSE APPLICATION TO FDA
CYTOGEN CORPORATION ANNOUNCES UPDATE ON FIRST QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
Cytogen to Acquire Advanced Magnetics.
Cytogen to Introduce Next-Generation Palladium Brachytherapy Seed Implant.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters